- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 213/50 - Radicaux cétoniques
Détention brevets de la classe C07D 213/50
Brevets de cette classe: 247
Historique des publications depuis 10 ans
|
30
|
13
|
16
|
17
|
15
|
7
|
5
|
8
|
16
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Biosplice Therapeutics, Inc. | 160 |
9 |
| Syngenta Limited | 422 |
7 |
| PTC Therapeutics, Inc. | 466 |
6 |
| Mycovia Pharmaceuticals, Inc. | 40 |
6 |
| Syngenta Crop Protection AG | 6756 |
5 |
| Chem-Master International, Inc. | 11 |
5 |
| Givaudan SA | 1987 |
5 |
| Johnson Matthey Public Limited Company | 1764 |
5 |
| Centre National de La Recherche Scientifique | 11111 |
4 |
| The Board of Trustees of the University of Illinois | 2754 |
4 |
| Novaled GmbH | 491 |
4 |
| Purdue Pharma L.P. | 432 |
4 |
| Lighthouse Pharmaceuticals, Inc. | 11 |
4 |
| The Regents of the University of California | 20902 |
3 |
| Epizyme, Inc. | 360 |
3 |
| Karyopharm Therapeutics Inc. | 145 |
3 |
| The Research Foundation for The State University of New York | 1768 |
3 |
| The Research Foundation of State University of New York | 363 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3015 |
3 |
| Xenthera, Inc. | 4 |
3 |
| Autres propriétaires | 158 |